SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase I drugs for Fallopian Tube Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGNB-7H4V’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SGNB-7H4V overview

SGNB-7H4V is under development for the treatment of variety of solid malignancies including epithelial ovarian cancer, cholangiocarcinoma, peritoneal cancer, fallopian tube cancer, human epidermal growth factor receptor 2 negative breast cancer (her2- breast cancer), triple-negative breast cancer, endometrial cancer, squamous non-small cell lung cancer, gallbladder cancer, adenoid cystic carcinoma (ACC) of the head and neck. It is administered by intravenous route. It is a vedotin ADC directed to the T cell checkpoint ligand, B7-H4. The drug candidate comprises of B7-H4 antibody conjugated with monomethyl auristatin E (MMAE). The drug candidate targets B7-H4 and developed based on antibody-drug conjugate (ADC) technology.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of SGNB-7H4V’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.